CancerDrs

Lymphoma clinical trials in North Dakota

11 actively recruiting lymphoma trials at 5 sites across North Dakota.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting Academic/Other

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05976763
Sites in North Dakota:
  • Sanford Bismarck Medical Center — Bismarck, North Dakota
  • Essentia Health Cancer Center-South University Clinic — Fargo, North Dakota
  • Sanford Broadway Medical Center — Fargo, North Dakota
  • Sanford Roger Maris Cancer Center — Fargo, North Dakota
Phase 3 Recruiting Network

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…

Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in North Dakota:
  • Sanford Broadway Medical Center — Fargo, North Dakota
Phase 3 Recruiting Academic/Other

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL). Sonrotoclax is in …

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07321652
Sites in North Dakota:
  • Sanford Bismarck Medical Center — Bismarck, North Dakota
  • Essentia Health Cancer Center-South University Clinic — Fargo, North Dakota
  • Sanford Broadway Medical Center — Fargo, North Dakota
  • Sanford Roger Maris Cancer Center — Fargo, North Dakota
Phase 2 Recruiting NIH

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in North Dakota:
  • Sanford Broadway Medical Center — Fargo, North Dakota
Phase 2 Recruiting Academic/Other

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE:…

Sponsor: American Society of Clinical Oncology
NCT ID: NCT02693535
Sites in North Dakota:
  • Sanford Health- Bismarck — Bismarck, North Dakota
  • Sanford Health- Fargo — Fargo, North Dakota
Phase 2 Recruiting NIH

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-li…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06124157
Sites in North Dakota:
  • Sanford Broadway Medical Center — Fargo, North Dakota
Phase 1, Phase 2 Recruiting Industry

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse lar…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06395103
Sites in North Dakota:
  • Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 1003) — Fargo, North Dakota
Phase 1, Phase 2 Recruiting Industry

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

Researchers are looking for new ways to treat children with different types of melanoma (skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these: * Advanced, which means cancer spread in the body or cannot be remove…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT02332668
Sites in North Dakota:
  • Call for Information (Investigational Site 0070) — Fargo, North Dakota
Recruiting Academic/Other

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in North Dakota:
  • Sanford Bismarck Medical Center — Bismarck, North Dakota
  • Essentia Health Cancer Center-South University Clinic — Fargo, North Dakota
  • Sanford South University Medical Center — Fargo, North Dakota
  • Southpointe-Sanford Medical Center Fargo — Fargo, North Dakota
  • Sanford Medical Center Fargo — Fargo, North Dakota
Recruiting Academic/Other

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …

Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in North Dakota:
  • Essentia Health Cancer Center-South University Clinic — Fargo, North Dakota
Recruiting Network

Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer …

Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT06002828
Sites in North Dakota:
  • Essentia Health Cancer Center-South University Clinic — Fargo, North Dakota
  • Sanford Broadway Medical Center — Fargo, North Dakota
  • Sanford Roger Maris Cancer Center — Fargo, North Dakota
  • Essentia Health - Jamestown Clinic — Jamestown, North Dakota

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-27